ABSTRACT
INTRODUCTION
Craniopharyngiomas are nonglial epithelial tumors arising from the sellar/suprasellar region. They account for 3% of all intracranial neoplasms and for 5-10% of intracranial tumours in children (19) . Histologically, craniopharyngiomas consist of two subtypes, the adamantinomatous (ACP) and the papillary (20) . The ACP is the most common form and predominantly affects young children. The treatment of craniopharyngiomas remains a significant challenge. Gross total resection or subtotal resection in combination with adjuvant conventional radiotherapy are currently the treatment options for the management of craniopharyngiomas, but complete resection of these tumors is not always possible due to their large size, calcification and adherence to crucial surrounding neurovascular structures (20) . Therefore, they are associated with a high rate of recurrence after incomplete therapy with significant ensuing morbidity and mortality.
Despite recent advances, the molecular mechanism that leads to ACP formation as well as markers of their development and progression are poorly understood.
ErbB2 protein, encoded by the HER2neu gene, belongs to a family of four homologous transmembrane receptors [epidermal growth factor receptor (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4] (11) . Dimerization of the receptor either with a twin receptor (homodimerization) or with one of its siblings (heterodimerization) occur after binding of the ligand to the receptor and leads to phosphorylation of the intracellular tyrosine kinase residues which serve as docking sites for various effectors and transcription factors that ultimately modulate various biological responses including proliferation, survival, migration, and differentiation (11) . Overexpression of the ErbB2 protein determined either by immunohistochemistry or amplification of the ErbB2 gene or both accounts for 20-25% of invasive ductal carcinomas, and is associated with aggressive clinical behavior in breast cancer patients (3) . Nevertheless, ErbB2 expression was also demonstrated in various human cancers other than breast, including ovarian and endometrial cancers (22, 27) . Therefore, ErbB2 has been the target for immunotherapy. The overexpression of ErbB2 in prolactinomas and regulation of prolactin gene expression by ErbB2 receptor ligands have also been shown (12, 28) .
Activating mutations of the gene encoding β-catenin have been demonstrated in the majority of human ACP cases (10) . This activating mutation makes the molecule refractive to downregulation by the APC-axin-GSK-3 β destruction complex (26) . Mutation in the β-catenin gene was suggested to play a pivotal role in tumor morphogenesis and epithelial differentiation of ACP (5) . Studies demonstrated a link between tumor cell migration in ACP and cells with an activated canonical Wnt signaling pathway, which is characterized by nuclear accumulation of β-catenin (17, 18) . Therefore, the β-catenin gene mutation and the nuclear accumulation of β-catenin demonstrated by immunohistochemistry are the characteristic features of ACP (10) . Most recently, the EGFR cascade was demonstrated to play also a role in Wnt signaling activation, perhaps because of a direct interaction between EGFR and β-catenin (23) .
Despite the overexpression of ErbB2 in various human cancers and pituitary adenomas (4, 22) , its expression in ACP, its relationship with nuclear β-catenin immunoreactivity, and its role in craniopharyngioma cell growth, survival and differentiation have not been determined so far. We therefore aimed to determine the immunohistochemical expression of ErbB2 in ACP and to assess its relationship with nuclear expression of β-catenin in surgically resected human ACP tissue sections and to estimate whether these tumors could be candidates for anti-ErbB2 therapy in this study.
MATERIAL and METHODS
For the present study, the paraffin-embedded tissue sections of 20 patients, operated at our center from 1993 to 2009 and diagnosed as adamantinomatous craniopharyngioma according to histopathological findings, were eligible for immunohistochemical analysis. Immunohistochemistry for ErbB2 was performed using avidin-biotin-peroxidase complex method. 3-5 µm cut formalin-fixed, paraffin embedded tumor tissue specimens underwent heat-induced antigen retrieval for 20 min in 0,01 M citrate buffer (PH 6.0) in the microwave. Sections were incubated for 60 minutes at room temperature with a mouse monoclonal anti-ErbB2 antibody (NCL-L-CB 11, Novocastra Laboratories, UK) at 1/40 dilution. Positive control consisted of invasive ductal carcinoma with 3+ staining for ErbB2. ErbB2 immunoexpression was evaluated on a multihead light microscope by two observers (C.T and F.K) and was interpreted according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/ CAP) criteria for breast carcinoma (score 0, no staining or membrane staining is observed in <10% of the tumor cells; score 1+, faint/barely perceivable membrane staining is detected in >10% of the tumor cells, and only part of the membrane is stained; score 2+, weak to moderate complete membrane staining is observed in >10% of the tumor cells; score 3+, strong complete membrane staining is observed in >30% of the tumor cells) (30) . Immunostaining for β-catenin was also performed using the same method and was evaluated by the same pathologists. A rabbit polyclonal antibody against β-catenin (Rb 9035-R7, Neomarkers Laboratories, USA) was used at 1/250 dilution. Data were analyzed using SPSS version 12.0.0 for Windows (SPSS Inc., Chicago, IL). Scale variables were presented as the mean ± standard deviation (mean ±SD) or percentages as appropriate. The project was approved by the local ethical board.
RESULTS
The present study included 20 patients ( 10 female, 10 male), ranged in age between 5-61 years old (24.9±17.38 years). Patient characteristics and immunohistochemistry results were presented in Table I . In this study, the provided tissues for immunohistochemistry were obtained at first surgery in 13 (65%) and at surgeries carried out after at least one recurrence in remaining 7 (35%) cases. Among the 20 cases
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evaluated, 2 (10%) were score 3+ for ErbB2 ( Figure 1A -C) and the remaining 18 cases were score 0 ( Figure 1D ). Patchy cytoplasmic staining was observed in 10 (50%) cases. ErbB2 positive cells were distributed randomly throughout the tumor cells but with higher amounts near to the surface squamous cells and in cells bordering the foci of ''wet keratinizations'' . Negative membrane staining was found in palisaded basal layer cells ( Figure 1C ). Different levels of ErbB2 positivity was also observed in cells of reactive gliosis bordering the tumors.
Foci of nuclear reactivity for β-catenin was observed in all ACP tissue specimens, mainly concentrated in epithelial cells within the whorl-like arrays, including those with 3+ ErbB2 immunoexpression ( Figure 1E ) However, cytoplasmic and membrane immunoreactivity for β-catenin was also found in some other portions of the ACP tissue specimens ( Figure 1F ). Membrane immunostaining for β-catenin was concentrated in areas of squamous cells and between areas of ''wet keratinizations'' and cysts. Nuclear and cytoplasmic β-catenin immunoreactivity was also observed in palisaded epithelial cells, in areas that were negative for ErbB2 ( Figure  1F ). However, no membrane immunoreactivity for ErbB2 was observed in whorl-like arrays of the epithelial cells, the area that mainly showed nuclear immunoreactivity for β-catenin.
Both patients with 3+ ErbB2 staining had large and invasive sellar/suprasellar tumors. One of these patients was a 12-yearold female who died soon after the first surgery and the other was a 30-year-old male patient who had undergone 3 consecutive surgeries and radiotherapy due to the recurrence of the tumor. He is being followed for panhypopituitarism, excessive weight gain and diabetes insipidus that developed after repeated surgeries and radiotherapy.
DISCUSSION
In the present study, 20 cases of ACP assessed for ErbB2 and β-catenin immunoexpression. Of the 20 cases evaluated, 2 (10%) demonstrated score 3+ immunoreactivity for ErbB2 and all of the cases showed nuclear immunoreactivity for β-catenin which is the hallmark of ACP (10).
β-catenin functions as a key mediator in the Wntsignaling pathway which is related to the cell proliferation, differentiation and migration (7) . Activation of β-catenin has been suggested to activate expression of a variety of target genes including Lef1, Axin1 and CyclinD1 (6), a major regulator of the progression of cells into the proliferative stage of the cell cycle. Andoniadou et al. indicated that nucleocytoplasmic β-catenin cluster cells act as a source of mitogenic and prosurvival for themselves and surrounding membranous β-catenin ACP cells by enhancing expression of mitogenic signals including members of the hedgehog-secreted signals, fibroblast growth factor and bone morphogenetic 
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(WHO) classification, they often behave as aggressive tumors and cause significant mortality and morbidity (19, 32) . Malignant transformation of craniopharyngiomas either after radiotherapy or without previous radiotherapy has also been reported (15) . The preferred goal of therapy for a craniopharyngioma is the total resection of the tumor. However, most of craniopharyngiomas invade the optic chiasma and other surrounding brain tissues as well as the vessels of the Circle of Willis, which preclude a total resection of the tumor (31) . On the other hand, recurrence could occur in 0-62% of cases after gross total resection and in 25-100% of cases after subtotal resection (21) . Recurrence may also occur in up to 20% of the cases after radiotherapy performed for residual disease (14) . So, there is no satisfying treatment option other than gross total or subtotal resection followed by adjuvant radiotherapy.
Trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of ErbB2, is used for the treatment of ErbB2 positive breast cancer. When combined with chemotherapy, trastuzumab has been demonstrated to be effective in patients with ErbB2-positive metastatic breast cancer (2). However, trastuzumab has also been demonstrated to be effective when used as single agent in the treatment of metastatic ErbB2-positive breast cancer (29) . Although trastuzumab does not cross the blood-brain barrier due to its large molecule size, its administration via the intrathecal route has been reported to be effective for brain metastasis of ErbB2 positive breast cancer (24) . In recent years, research efforts have focused on improving the delivery of trastuzumab to the Our study results were consistent with all of these studies and indicated nuclear accumulation of β-catenin in all of the ACP tissue specimens, predominantly accumulated in epithelial cells within the whorl-like arrays (7, 8) . Our results also support that aberrant nuclear β-catenin expression may be involved in morphogenesis and growth of ACP (5, 8) . However, the localization of cells with nuclear β-catenin immunoreactivity which was mainly accumulated in epithelial cells within the whorl-like arrays was different from cells with 3+ ErbB2 immunoreactivity. So, if the ErbB2 protein plays a role in tumor growth, survival or differentiation of some ACP, the mechanism of action may be different from β-catenin pathway. However, because of the small number of ACP, particularly those with score 3+ ErbB2 expression, the effect of ErbB2 protein in ACP cell growth, survival and differentiation should be determined in functional studies with larger sample sizes.
Although craniopharyngiomas correspond histologically to tumoral grade I according to the World Health Organization The expression of ErbB2 was also demonstrated in both functioning and non-functioning pituitary adenomas, particularly in those showing aggressive behavior (9) . The regulation of hormonal secretion, cell morphology and proliferation by ErbB2 tyrosin kinase inhibitors was also shown in experimental studies (9) . In a study conducted by Fukuoka et al. lapatinib was shown to suppress both prolactin mRNA expression and secretion in cultured human prolactinoma tissues (12) . In the same study, Lapatinib treatment was also demonstrated to cause tumor shrinkage and serum prolactin suppression both in HER2CA transfectant-inoculated WistarFurth rats and in estrogen-induced Fischer rat prolactinomas (12) . Most recently, Fukuoka et al. demonstrated also supressed expression of proopiomelanocortin by gefitinib, a EGFR tyrosin kinase inhibitor, in surgically resected human and canine corticotroph cultured tumors (13). Hölsken et al analyzed the effect of EGFR activation on cell motility in 11 primary ACP cell cultures. They found increased migration and invasion capacity with activation of the EGFR. They also found reduced motility of activated EGFR when exposed to gefitinib (16) . A significant enhanced expression of Fascin, the target gene of β-catenin, was also found after EGFR activation that was inhibited in the majority of cases by gefitinib treatment (16) . All of these studies highlight the importance of targeted therapeutics for the treatment of pituitary adenomas and ACP. However, to date, the expression of ErbB2 had not been determined in craniopharyngioma of any subtype.
In this study 2 cases were score 3+ for ErbB2 and both cases were large and sellar/suprasellar tumors and one of them was a tumor with more than one recurrence. However, as demonstrated in table 1, most of the tumors, including 5 other recurrent cases were negative for ErbB2. Therefore, due to the small cohort of tumors, the association between ErbB2 protein and recurrence of ACP should be determined in further studies.
In summary, our preliminary data demonstrate score 3+ staining for ErbB2 in 10% of ACP and different localization of 3+ ErbB2 cells and cells with nuclear β-catenin immunoreactivity. However, because of the small number of cases, further studies with larger samples should be conducted to verify and validate our preliminary data and to determine the effect of ErbB2 protein in ACP cell growth, survival and differentiation.
